Abstract
Experimental evidence confirms that interleukin-10 plays a critical role in clearing acute hepatitis B virus infection. This paper aims to develops a mathematical model to explore the dynamics of how the immune system responds to hepatitis B virus (HBV) and coexisting liver cancer within the liver cell population. Unlike previous models; we categorize liver cells into various stages of infection. We determine the invasion probability for transmission dynamics, specifically the basic reproduction number, ℝ0, for populations of uninfected macrophages with and without cancer cells. Stability analyses of virus-free and virus equilibrium states are provided, along with numerical simulations to validate analytical findings. The impact of different branches of the immune response on model dynamics is assessed. Simulations predict the time at which T helper-1 cells surpass cytotoxic T cells (switching time), correlating positively with the proliferation rate of interleukin-10 (ρ3). Further numerical simulations demonstrate that interleukin-10 contributes to HBV persistence by inhibiting the immune response, thereby allowing the virus to evade immune surveillance and establish chronic infection through the suppression of cytotoxic T lymphocytes (CTLs), which are essential for clearing infected cells.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
